Adverum appoints Linda Rubinstein as full-time CFO; $485K salary, 850K share option

Adverum Biotechnologies, Inc.

Linda Rubinstein transitions from consulting CFO (via FLG Partners) to full-time CFO effective Aug 3, 2023.
Base salary $485,000; target bonus 40%; option for 850,000 shares vesting over 36 months with 25% cliff at 6 months.
Severance: 12 months salary plus equity vesting if termination near change in control; 9 months otherwise; reduced to 3 months in first year.
Consulting agreement with FLG Partners terminated as of start date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Linda Rubinstein

Chief Financial Officer

Adverum Biotechnologies, Inc.

Effective: 2023-08-03
Filed: August 4, 2023, 7:59 PM ET

On August 3, 2023, Ms. Rubinstein and Adverum entered into an employment offer letter (the “Offer Letter”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Linda Rubinstein was appointed as Chief Financial Officer at Adverum Biotechnologies, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 3, 2023, Ms. Rubinstein and Adverum entered into an employment offer letter (the “Offer Letter”).

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-203894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.